Bruker Co. (NASDAQ:BRKR) Stake Lifted by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC boosted its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 0.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,495,686 shares of the medical research company's stock after purchasing an additional 13,385 shares during the quarter. Bruker comprises 16.5% of Pallas Capital Advisors LLC's portfolio, making the stock its largest position. Pallas Capital Advisors LLC owned about 6.26% of Bruker worth $396,350,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB increased its stake in Bruker by 274.9% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock worth $46,000 after acquiring an additional 800 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Bruker by 45.8% during the 1st quarter. UMB Bank n.a. now owns 1,325 shares of the medical research company's stock worth $55,000 after purchasing an additional 416 shares during the period. Quadrant Capital Group LLC increased its position in Bruker by 18.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after purchasing an additional 196 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Bruker by 41.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock valued at $78,000 after buying an additional 390 shares during the period. Finally, Parvin Asset Management LLC acquired a new position in Bruker during the fourth quarter valued at approximately $112,000. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Stock Up 1.6%

Shares of NASDAQ BRKR opened at $38.30 on Monday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. Bruker Co. has a 1 year low of $34.10 and a 1 year high of $72.94. The stock's 50-day simple moving average is $38.16 and its 200-day simple moving average is $48.43. The firm has a market cap of $5.80 billion, a price-to-earnings ratio of 50.40, a PEG ratio of 2.16 and a beta of 1.16.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.01. The company had revenue of $801.40 million for the quarter, compared to the consensus estimate of $763.83 million. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Bruker's revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.53 EPS. As a group, equities analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Monday, June 16th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.52%. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. The Goldman Sachs Group dropped their price objective on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Barclays lowered their price target on Bruker from $50.00 to $46.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Stifel Nicolaus cut their price objective on Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a research report on Thursday, May 8th. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a research report on Monday, February 24th. Finally, Wells Fargo & Company lowered their target price on Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $56.22.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.